Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions.

Ziena AbdulrahmanNatasja HendriksArnold J KruseAntonios SomarakisAnna J M van de SandeHeleen J van BeekhuizenJurgen M J PiekNoel F C C de MirandaLoes F S KooremanBrigitte F M SlangenSjoerd H Van der BurgPeggy J de Vos van SteenwijkEdith M G van Esch

Published in: Journal for immunotherapy of cancer (2022)

The capacity of cHSIL patients to respond to imiquimod is associated with a pre-existing coordinated local immune process, fostering an imiquimod-mediated increase in local T cell infiltration. The CIBI immunohistochemical biomarker has strong potential to select cHSIL patients with a high likelihood to experience a complete response to imiquimod immunotherapy.

Keyphrases

high grade
low grade
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors